CA9 and neoplasm: This finding supports clinical evidence observed in a trial of carbonic anhydrase IX (CAIX)-targeted CAR-T cells where off-tumor CAR-T cell activation against target antigen expressed on bile duct epithelial cells drove a CD4+ T cell-biased hepatic toxicity (only scattered CD8+ T cells were present).20